lilotomab
mAbexperimental
Lilotomab is a murine monoclonal antibody against CD37, a glycoprotein which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital. — Wikipedia
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2012 (NCT01796171)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Leukocyte antigen CD37Supplementation
CD37 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLilotomab ↗
- ChEMBLCHEMBL4802260 ↗
Also known as
- betalutin
- betalutin
- betalutin
- lilotomab
- tetulomab tetraxetan lu-177
- tetulomab tetraxetan lu-177
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03806179 | Phase 1 | Oct 4, 2018 | ICON, Thor Medical, University of Oslo |
| NCT02657447 | Phase 1 | May 1, 2017 | Julius-Maximilians University, Thor Medical |
| NCT02658968 | Phase 1 | Jan 1, 2016 | Thor Medical, University of Manchester |
| NCT01796171 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2012 | ICON, Osaka University, Thor Medical |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Thor Medical | For profit | 4 | 4 | 2 | 2012 |
| ICON | For profit | 2 | 0 | 2 | 2012 |
| Julius-Maximilians University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Osaka University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Oslo | Academic/Hospital | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1